Neumora Therapeutics, Inc. (NMRA) AI Stock Analysis

• Market Cap: $272.07M
• Dividend Yield: N/A
• Average Volume (3M): 875.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.28
• Revenue Growth: N/A
• EPS Growth: 9.84%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 161,945,430
• 10 Day Avg. Volume: 359,382
• 30 Day Avg. Volume: 875,641
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.29
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.30
• 1Y Price Target: $8.25
• Price Target Upside: 391.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 33 Underperform
• Price Target: ―

Neumora Therapeutics, Inc. is significantly challenged by its financial position, with ongoing losses and no revenue. Technical analysis indicates bearish momentum, and valuation is difficult in the absence of earnings. While promising pipeline advancements and a strong cash position offer some optimism, the overall outlook is hindered by recent clinical setbacks and financial instability.

Positive Factors

Market Reaction

NMRA's shares have increased significantly since the announcement of the new M4 PAM candidate, indicating market embrace of the news.

New Product Introduction

NMRA has introduced NMRA-861, a new M4 PAM candidate for schizophrenia and other neuropsychiatric disorders, which has advanced into the clinic.

Strategic Development

Neumora announced it will be prioritizing obesity as lead indication for NMRA-215, the company’s highly brain-penetrant NLRP3 inhibitor.

Negative Factors

Financial Constraints

Neumora may need to raise additional capital to fund the development of its pipeline, indicating potential financial challenges.

Historical Setbacks

The stock is still suffering from the fallout of first negative P3 KOASTAL-1 data for navacaprant in depression.

Regulatory Challenges

Risks include the regulatory challenge as none of Neumora's products has been approved by the FDA.

Neumora Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Neumora Therapeutics, Inc. generates revenue through the development and commercialization of its precision medicines. The company focuses on advancing its pipeline of investigational therapies through various stages of clinical trials, aiming for regulatory approval and subsequent market entry. Revenue is primarily derived from the successful commercialization of approved drugs. Additionally, Neumora may engage in strategic partnerships and collaborations with other pharmaceutical companies, which can include licensing agreements, joint ventures, or co-development arrangements, providing additional revenue streams and resources to support its research and development activities.

Neumora Therapeutics, Inc. Financial Statement Overview

Summary

Neumora Therapeutics, Inc. faces significant financial challenges with no revenue and substantial ongoing losses. While it maintains a strong cash position, financial instability is highlighted by negative equity and consistent cash outflows, indicating a dependency on external capital.

Income Statement

Neumora Therapeutics, Inc. has consistently reported zero revenue over the past several years, indicating a lack of monetization. All profitability metrics are negative, reflecting the company's inability to generate income. The company has significant ongoing losses, with a worsening EBIT and Net Income, suggesting high operational costs and financial strain typical for early-stage biotechnology firms.

Balance Sheet

The company maintains a strong cash position relative to its total assets, indicating good liquidity. However, continuing losses have resulted in negative equity in some years, posing a risk. The debt-to-equity ratio is not meaningful due to negative equity in prior periods, but low total debt suggests limited leverage. The equity position improved slightly, but overall financial health is weak.

Cash Flow

Neumora Therapeutics, Inc. shows consistent negative free cash flow, reflecting cash burn typical of R&D-heavy biotechnology companies. The cash flow from financing activities has been positive, indicating reliance on external funding to support operations. The operating cash flow has been negative, consistent with the lack of revenue generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-668.00K	-2.70M	-1.55M	0.00
EBITDA	-264.23M	-242.98M	-187.53M	-135.28M	-236.78M	-95.41M
Net Income	-252.09M	-243.79M	-235.93M	-130.90M	-237.31M	-99.27M
Balance Sheet
Total Assets	223.82M	316.97M	496.19M	426.23M	429.30M	197.95M
Cash, Cash Equivalents and Short-Term Investments	217.59M	307.58M	453.98M	371.88M	409.25M	191.98M
Total Debt	510.00K	1.85M	5.23M	8.44M	2.05M	2.04M
Total Liabilities	40.95M	29.91M	27.12M	873.08M	754.52M	292.33M
Stockholders Equity	182.88M	287.06M	469.08M	-446.85M	-325.22M	-94.38M
Cash Flow
Free Cash Flow	-194.90M	-182.94M	-163.40M	-115.41M	-76.24M	-28.06M
Operating Cash Flow	-195.68M	-182.94M	-163.28M	-114.90M	-75.42M	-26.76M
Investing Cash Flow	132.75M	-70.56M	64.39M	-168.01M	-817.00K	-11.24M
Financing Cash Flow	35.56M	21.60M	231.94M	115.74M	293.51M	230.10M

Neumora Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.68
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMRA, the sentiment is Neutral. The current price of 1.68 is above the 20-day moving average (MA) of 1.64, above the 50-day MA of 1.54, and below the 200-day MA of 2.72, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 52.17 is Neutral, neither overbought nor oversold. The STOCH value of 38.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NMRA.

Neumora Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	64 Neutral	$192.96M	―	-48.36%	―	333.74%	―
Sector *	51 Neutral	$7.95B	-0.40	-42.50%	2.21%	22.29%	-1.85%
EDIT	51 Neutral	$248.18M	―	-188.58%	―	-41.97%	-20.86%
NKTX	39 Underperform	$160.52M	―	-26.94%	―	―	26.33%
RAPT	39 Underperform	$213.83M	―	-77.83%	―	―	43.16%
ALDX	37 Underperform	$333.02M	―	-65.91%	―	―	-32.74%
NMRA	33 Underperform	$272.07M	―	-89.37%	―	―	9.84%

Neumora Therapeutics, Inc. Corporate Events

Neumora Therapeutics Announces Leadership Changes and Strategy

On February 13, 2025, Neumora Therapeutics announced leadership changes effective February 14, 2025, with Paul L. Berns transitioning to CEO and Chairman of the Board. Other key executives such as Joshua Pinto, Bill Aurora, and Michael Milligan have been assigned new roles. These changes are part of the company’s strategic efforts to enhance its position in the industry. Additionally, the Board approved an option repricing plan to incentivize key personnel, subject to stockholder approval, reflecting Neumora’s commitment to retaining talent while advancing its neuroscience initiatives.